TMCnet News
Sanjeev Luther, President and CEO of Rafael Pharmaceuticals, to be Honored by American Cancer Society at Annual Starry Night GalaNewark, NJ, May 16, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that Sanjeev Luther, President and Chief Executive Officer, was named the 2019 Corporate Honoree by the American Cancer Society (ACS). This prestigious honor will be given to Mr. Luther on May 18th at the 12th Annual Starry Night Gala. Mr. Luther’s passion for driving cancer research can be reflected in the success he has made at Rafael Pharmaceuticals. The company is developing a new, first-in-class category of metabolic oncology therapeutics that attacks hard-to-treat cancers by targeting the metabolic processes the disease needs to survive, grow and proliferate. Under Mr. Luther’s leadership, Rafael has made significant progress in its clinical development, including two Phase 3 programs of its lead molecule CPI-613® (devimistat) for patients with metastatic pancreatic cancer and relapsed or refractory acute myeloid leukemia (AML) and several orphan designations. Mr. Luther also brings thirty years of experience to Rafael from leading Fortune 500 pharmaceutical companies. “I would like to thank the ACS for this truly humbling honor,” said Mr. Luther. “It is because of the researchers, leaders, volunteers and staff at the ACS that there is hope for patients, survivors and families. Together, with ACS and the passionate team at Rafael, I believe that we will continu to positively impact lives and make advancements for future generations as we live by Rafael's motto, ‘To Save A Life Is To Save A Universe.’” The Starry Night Gala is held each year to celebrate the accomplishments of the ACS and to look forward to future successes by raising money for more research, treatment options, and survivors. It is attended by healthcare professionals, top business leaders and philanthropic individuals. Honorees, or “Inspirers of Hope,” are recognized each year for their dedication to cancer research, cancer treatment and cancer recovery. Mr. Luther will be one of four honorees recognized at this year’s event. About Rafael Pharmaceuticals, Inc. Safe Harbor Statement In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. ### Company Contact: Media Contact: |